PROGRESSION-FREE SURVIVAL 16.6 MONTHS FOR OPDIVO/CABOMETYX VS 8.3 MONTHS FOR SUNITINIB -PHASE III STUDY
Progression-Free Survival 16.6 Months For Opdivo/Cabometyx Vs 8.3 Months For Sunitinib -Phase Iii Study
![Reuters logo](/images/reuters.jpg)
PROGRESSION-FREE SURVIVAL 16.6 MONTHS FOR OPDIVO/CABOMETYX VS 8.3 MONTHS FOR SUNITINIB -PHASE III STUDY